RE:RE:RE:RE:ArticleIn my opinion this is a half-assed article.
She maintained her buy rating, and the $1.70 target.
Why would she do that if everything is so seriously downgraded.
Is it because these projections were always in flux, and as a result she initially used an extremely low multiple?
Ultimately MBX is an evolving story. In my opinion its a fantastic story, that includes VTM which is not yet a "universal" VTM and has not been offered to the world because of capacity constraints.
It also includes QAP's which is at the very beginning of huge upswing as they work directly with the testing companies and labs, as well as a distribution network that for all intents and purposes was born yesterday.
Finally, we have our free "option" on Kinlytic.
This "Simply Wall St." synopsis of the IA letter is very flawed in my opinion.
The management team has delivered at a very high level in 2021.
As a shareholder I am grateful for the hard work and performance of the company, and I am excited about our prospects for 2022. Not selling a share, will likely be buying more.